Aileron Therapeutics Inc
NASDAQ:ALRN 3:50:01 PM EDT
Regulatory, Other Pre-Announcement
Aileron Therapeutics Provides Business Update And Outlines 2021 Strategic Priorities
Published: 12/21/2020 16:26 GMT
Aileron Therapeutics Inc (ALRN) - Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities.
Aileron Therapeutics - Anticipated Milestones Include Reporting Initial Results From Phase 1b Nsclc Clinical Trial in Q4 2021.
Aileron Therapeutics Inc - in 2021, Plans to Report Additional Results From Ongoing Phase 1b Clinical Trial in Patients With Sclc.
Aileron Therapeutics - Due to Covid-19-related Delays, Updating Guidance on Readout of Healthy Volunteer Study From Q2 of 2021 to Mid-2021.
Aileron Therapeutics - Anticipated Milestones Include Reporting Initial Results From Phase 1b Nsclc Clinical Trial in Q4 2021.
Aileron Therapeutics Inc - in 2021, Plans to Report Additional Results From Ongoing Phase 1b Clinical Trial in Patients With Sclc.
Aileron Therapeutics - Due to Covid-19-related Delays, Updating Guidance on Readout of Healthy Volunteer Study From Q2 of 2021 to Mid-2021.